Comparative Pharmacology
Head-to-head clinical analysis: NALLPEN versus PENICILLIN 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NALLPEN versus PENICILLIN 2.
NALLPEN vs PENICILLIN-2
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
NALLPEN (naloxone) is a competitive opioid receptor antagonist that binds to mu, kappa, and delta opioid receptors, reversing the effects of opioid agonists including respiratory depression, sedation, and hypotension.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
1 gram IV every 8 hours over 30 minutes.
250 mg orally every 6 hours or 500 mg orally every 8 hours for mild to moderate infections; intravenous dosing: 1-2 million units every 4-6 hours.
None Documented
None Documented
Terminal elimination half-life is 2.0-3.0 hours; prolonged in renal impairment (up to 24 hours).
30-60 minutes; prolonged in renal impairment (up to 10 hours in anuria)
Primarily renal excretion (80-90% unchanged) with minor biliary/fecal elimination (5-10%).
Renal: 60-80% unchanged; biliary/fecal: minor (10-20%)
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic